基岩
医学
肺结核
重新调整用途
药理学
重症监护医学
抗药性
结核分枝杆菌
药品
临床试验
疾病
药物重新定位
广泛耐药结核
内科学
病理
微生物学
生物
生态学
出处
期刊:Current Molecular Pharmacology
[Bentham Science]
日期:2023-06-01
卷期号:16 (3): 243-253
标识
DOI:10.2174/1874467215666220421130707
摘要
Mycobacterium tuberculosis causes a contagious pulmonary disease with a high mortality rate in developing countries. However, the recommendation of DOTS (approved by WHO) was effective in treating tuberculosis, but nowadays, resistance from the first line (MDR-TB) and the second line (XDR-TB) drugs is highly common. Whereas, the resistance is a result of factors like poor patient constancy due to the long duration of therapy and co-infection with HIV. The approval of bedaquiline under an accelerated program for the treatment of MDR-TB has revealed its effectiveness in clinical trials as a therapeutic novel molecule. BDQ selectively inhibits the ATP synthase of bacterium and reduces ATP production. Additionally, the poor pharmacokinetic properties raised provocations in the MDR therapy, but the use of targeted drug delivery can solve the hurdles. While the preclinical and clinical studies included in this review are strongly suggesting the usefulness of BDQ in MDR-TB and XDR-TB, the repurposing of different drug classes in resistant TB is opening new opportunities to manage the disease conditions. In this review, we have summarized the examples of pipeline drugs and repurposed molecules with preclinical formulation developments.
科研通智能强力驱动
Strongly Powered by AbleSci AI